In the current global market environment, characterized by cautious commentary from the Federal Reserve and looming political uncertainties, investors are navigating a landscape of mixed economic signals. Despite these challenges, opportunities may exist in identifying stocks trading below their intrinsic value, offering the potential for long-term growth as market conditions stabilize. In such an environment, a good stock is often one that demonstrates strong fundamentals and resilience amid broader market volatility.
|
Name |
Current price |
Fair value (East) |
Discount (East) |
|
Clearly Safe (NYSE:YOU) |
$26.66 |
US$53.14 |
49.8% |
|
Sudarshan Chemical Industry (BSE:506655) |
₹1129.90 |
₹2252.82 |
49.8% |
|
Hansa (OM:HANZA) |
€76.20 |
151.92 SEK |
49.8% |
|
HealthEquity (NasdaqGS:HQY) |
US$94.95 |
$189.22 |
49.8% |
|
Andean Waters (SNSE:AGUAS-A) |
CLP293.50 |
CLP584.13 |
49.8% |
|
Ingenia Communities Group (ASX:INA) |
A$4.62 |
A$9.19 |
49.7% |
|
South Atlantic Bank Stocks (OTCPK:SABK) |
$15.02 |
US$29.98 |
49.9% |
|
KebNi (OM:KEBNI B) |
SEC1.09 |
SEC2.17 |
49.8% |
|
RENK group (DB:R3NK) |
€18,342 |
€36.50 |
49.7% |
|
iFLYTEKLTD (SZSE:002230) |
CN¥51.75 |
CN¥103.29 |
49.9% |
Click here to see the full list of 875 stocks from our Undervalued Stocks by Cash Flows screener.
Below we present a selection of stocks filtered out by our screen.
Overview: Revenio Group Oyj specializes in ophthalmic devices and software solutions for the diagnosis of glaucoma, macular degeneration and diabetic retinopathy in Finland, Europe, North America and internationally, with a market capitalization of €714.37 million.
Operations: The company generates revenues of €102.49 million from its Health Tech segment, with a focus on ophthalmic equipment and software solutions.
Estimated discount to fair value: 29.4%
Revenio Group Oyj is trading at €26.86, significantly lower than its estimated fair value of €38.02, indicating potential undervaluation based on cash flows. Despite a slight decline in net profit in the third quarter to €4.2 million compared to the previous year, sales are expected to grow by 12.2% annually, surpassing the Finnish market’s growth rate of 2.6% is exceeded. Furthermore, profits are expected to grow by 19% per year, exceeding local market expectations of 14.2%.
Overview: Surgical Science Sweden AB (publ) develops and sells virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia and internationally, with a market capitalization of SEK 8.24 billion.
Operations: The company generates revenue through its Industry/OEM segment, which contributes SEK 419.66 million, and its Educational Products segment, which contributes SEK 440.17 million.
Estimated discount to fair value: 49.2%
Surgical Science Sweden is trading at SEK 161.5, significantly lower than its estimated fair value of SEK 317.61, indicating undervaluation on a cash flow basis. Despite a decline in net profit for the third quarter and first nine months of 2024 compared to the previous year, sales are expected to grow by 17.7% annually, surpassing the Swedish market’s growth rate of 1.3% surpassed. Profits are expected to grow significantly by 36.1% per year, exceeding local expectations.
Overview: Mo-BRUK SA is active in the waste management industry, processing industrial, hazardous and municipal waste in several European countries, including Poland, Germany and Italy, with a market capitalization of PLN 1.13 billion.
Operations: The company’s revenue segments include processing industrial waste (PLN 163.48 million), hazardous waste (PLN 173.92 million) and municipal waste (PLN 89.56 million).
Estimated discount to fair value: 46.7%
Mo-BRUK is trading at PLN 322, significantly below its estimated fair value of PLN 603.73, indicating undervaluation based on cash flows. Despite a slight decline in net profit in the first nine months of 2024 compared to the previous year, sales and profits are expected to grow faster than the Polish market, at 11.3% and 23.7% annually, respectively. However, the dividend yield of 4.09% is not well covered by the free cash flows.
-
Click here to access our full index of 875 undervalued stocks by cash flow.
-
Shareholder in one or more of these companies? Make sure you’re never faced with any surprises by adding your portfolio to Simply Wall St so you get timely updates on important stock developments.
-
Maximize your investment potential with Simply Wall St, the comprehensive app that provides free global market insights.
This article from Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only an unbiased methodology and our articles are not intended as financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. We aim to provide you with targeted, long-term analysis based on fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or quality material. Simply Wall St has no positions in the stocks mentioned.
Companies discussed in this article include HLSE:REG1V OM:SUS and WSE:MBR.
Do you have feedback on this article? Worried about the content? Please contact us directly. You can also send an email to redactieteam@simplywallst.com
